12P A phase II study of atezolizumab in combination with bevacizumab, carboplatin or cisplatin, and pemetrexed for EGFR-mutant metastatic NSCLC patients after failure of EGFR TKIs

S-G Wu,C-C Ho,J.C Yang,B-C Liao,C-Y Yang,Y-T Lin,C-J Yu,W-Y Liao,J-Y Shih

doi:10.1016/j.annonc.2022.02.021

12P A phase II study of atezolizumab in combination with bevacizumab, carboplatin or cisplatin, and pemetrexed for EGFR-mutant metastatic NSCLC patients after failure of EGFR TKIs

S-G Wu, C-C Ho + Show 7 more

Open Access

https://doi.org/10.1016/j.annonc.2022.02.021

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Apr 1, 2022
Citations: 2	License type: elsevier-specific: oa user license

Affiliation: National Taiwan University Hospital

#EGFR-mutant NSCLC #Failure Of EGFR TKIs + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Acquired resistance to EGFR TKI remains a significant barrier for patients with EGFR-mutated lung cancer, especially for those without acquired EGFRT790M. The current study explored the safety and efficacy of combinational treatment with atezolizumab, bevacizumab, and pemetrexed-platinum in patients with EGFR-mutated NSCLC after failure of EGFR TKIs.

Full Text